Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Placebo
Lemborexant 10 mg
+2 more
Locations
11
United States
Pulmonary Associates
Glendale, Arizona, United States
Pacific Research Network
San Diego, California, United States
Teradan Clinical Trials
Brandon, Florida, United States
St. Francis Medical Institute
Clearwater, Florida, United States
Research Centers of America
Hollywood, Florida, United States
Clinical Trials of Florida, LLC
Miami, Florida, United States
Start Date
January 6, 2021
Primary Completion Date
February 10, 2022
Completion Date
February 10, 2022
Last Updated
October 10, 2023
NCT06712563
NCT07518472
NCT07446634
NCT03109171
NCT05429983
NCT07191314
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions